利邦(00891.HK)接獲聯交所復牌指引
格隆匯7月6日丨利邦(00891.HK)公佈,公司於2021年6月30日接獲聯交所通知以下公司股份恢復買賣的指引:(i)根據上市規則的規定刊發所有尚未公佈的財務業績,並提出任何審計修訂意見;(ii)證明遵守上市規則第13.24條;及(iii)向市場提供所有重要資料,讓公司股東及其他投資者評估公司的狀況。
聯交所要求公司於其證券獲准恢復買賣前,須對引致其暫停買賣的事項作出補救,並完全遵守上市規則以令聯交所信納,而就此目的,公司負有主要責任制定其復牌的行動計劃。聯交所亦表示,倘公司的情況有所變動,則其可修訂或補充復牌指引。
此外,公司股份繼續停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.